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Abstract
Non-alcoholic fatty liver disease (NAFLD) is increasingly evolving and a critical 
public health concern, raising the likelihood of liver cirrhosis, type 2 diabetes and 
cardiac problems. Existing epidemics of obesity and sedentary life style have lead 
to NAFLD’s elevated prevalence. In recent years there is profound change in the 
diet pattern, particularly the hypercaloric fat and carbohydrates for preventing or 
treating chronic liver disorders such as NASH and NAFLD. Functional and nutri-
tional foods have contributed significantly to NAFLDimprovement and manage-
ment. The justification for exploring functional foods as anti-NAFLD candidates 
for the chronic liver disease prevention is derived knowledge from in vitro and in 
vivo models. The findings from the in vitro and in vivo studies confirmed that these 
compounds are healthy, efficient, reversible inhibitors, when sufficiently consumed 
over a lifetime without severe toxicity, suitable for clinical trials and potentially 
becoming low-cost medication.
Keywords: non-alcoholic fatty liver disease, functional foods, phenolics, flavonoids, 
treatment, management
1. Introduction
Non-alcoholic fatty liver disease (NAFLD) is the primary liver disease posing 
severe health and economic burden worldwide [1]. NAFLD is characterized with 
excessive fat storage in the liver, constituting up to 10% of the total liver weight [2]. 
NAFLD is typically caused due to reasons other than excessive alcohol intake such 
as obesity, insulin resistance, diabetes mellitus, high triglycerides, dyslipidemia, 
etc. [3]. Based on liver histology, NAFLD is further classified into the non-alcoholic 
fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH). NAFL is character-
ized by retention of fat in the liver without hepatocyte injury, whereas in NASH, 
significant inflammation, hepatocyte injury and liver steatosis are observed [4]. 
The progression of NASH is quite complicated and if unattended, will lead to liver 
fibrosis, cirrhosis, hepatocellular carcinoma and organ transplantation. At present, 
there is no FDA approved drug for the management of NAFLD. Functional foods 
are being prepared using scientific intelligence to provide the required amount of 
macro and micronutrients for once health. Compared to conventional foods, func-
tional foods deliver potentially nutritious components that reduce the risk of several 
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chronic diseases [5]. Nutraceuticals are any food substance or part of a diet that 
afford significant health benefits [6]. This chapter will emphasize the importance of 
functional foods and nutraceuticals for the management of NAFLD.
2. Prevalence and pathogenies of NAFLD
NAFLD, the primary cause of chronic liver disease seen in developed countries, 
is presently highly prevalent among the Asian population. According to recent 
estimates, the global prevalence of NAFLD is reported at 25 percent and the com-
bined prevalence rate is 27.4 percent in Asia [7]. Two hypotheses are framed for the 
pathogenesis of NAFLD. The first hit is a two-hit theory where fat accumulation in 
the liver is caused due to diet, obesity and insulin resistance and the first hit further 
exposes the liver to more insults called second hit which activate inflammatory 
pathways and fibrogenesis [8]. In continuation, a multi-hit hypothesis was sug-
gested where numerous factors like environment, dietary habits and genetic led to 
the development of liver damage [9].
3. Key factors involved in the progression of NAFLD
3.1 Lipid accumulation and insulin resistance
Triglyceride accumulation in hepatocytes is a significant factor in the develop-
ment of NAFLD. Glycerol and fatty acids undergo esterification to form triglyc-
erides (TGs), which are usually stored or secreted. The fate of the fatty acids is 
to either undergo esterification or enter the β-oxidation pathway. Under normal 
conditions, TGs are not toxic; where they maintain free fatty acids [10]. Studies 
have shown increased de-novo lipogenesis and expression of transcription factors 
such as sterol regulatory element binding protein-1c (SREBP-1c), carbohydrate 
response element-binding protein (ChREBP) and peroxisome proliferator-activated 
receptor-γ (PPAR-γ) in NAFLD [11]. Insulin resistance is another critical factor 
in NAFLD that drive the activation of de-novo lipogenesis. Insulin receptor sub-
strate-2 (IRS-2) is known to regulate SREBP-1c negatively. Insulin resistance also 
lead to decreased oxidation of free fatty acids; hence fat accumulate in the hepato-
cytes. Free fatty acids in hepatocytes also inhibit the insulin signaling through the 
serine-kinase pathway leading to insulin resistance [12]. Accumulation of fat in the 
liver also contribute to stress and dysfunction to mitochondria and endoplasmic 
reticulum (ER). Dysfunctional mitochondria lead to increased reactive oxygen spe-
cies (ROS) generation and activation of inflammatory pathways leading to hepatic 
necro-inflammation and further damage of mitochondria (Figure 1) [13].
3.2 Cytokines
Studies have shown the involment of cytokines during liver inflammation, liver 
fibrosis, liver regeneration and hepatocyte apoptosis [14]. In obese individuals, 
adipose tissue is enlarged and release various adipokines, which further recruit 
macrophages resulting in the secretion of pro-inflammatory adipokines [15]. 
Increased leptin levels play a crucial role in NAFLD progression by inducing insulin 
resistance and steatosis development [16]. Adiponectin, an anti-inflammatory 
adipokine secreted exclusively by the adipocytes, plays a protective role in the 
liver by preventing lipid accumulation through enhanced β-oxidation of free fatty 
acids [17]. Lipid accumulation, insulin resistance, mitochondrial stress, ER stress 
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and fatty dysfunction have contributed to the generation of pro-inflammatory 
cytokines. c-Jun N-terminal kinase/activator protein 1 (JNK/AP-1), tumor necrosis 
factor-α (TNF-α) and nuclear factor kappa-light-chain-enhancer of activated B 
cells (NF-κB) are some of the crucial players in the development of inflammation in 
NAFLD. JNK pathway lead to apoptosis and progression of NAFL to NASH. NF-κB 
activation lead to chronic hepatocyte inflammation and insulin resistance [18].
3.3 Genetic, epigenetic and dietary factors
Gene mutations like single nucleotide polymorphisms (SNPs) influence the 
free fatty acids secreted from hepatocytes to release cytokines, further stimulating 
NAFLD progression [19]. An example of SNP that affect NAFLD progression is the 
patatin-like phospholipase 3 (PNPLA3) gene. Lipid accumulation in hepatocytes of 
a PNPLA3 gene mutant carrier is associated with lower lipoprotein secretion, which 
is rich in liver TGs [20]. Pirazzi et al. (2012) showed that humans with PNPLA3 
mutation exhibited increased steatosis and fibrosis. Transmembrane 6 superfam-
ily member 2 (TM6SF2) mutation is also associated with NAFLD [21]. Wild type 
TM6SF2 protein promote VLDL secretion, while its variant is associated with 
hepatic steatosis caused by lower VLDL secretion and high ALT levels [22].
Epigenetic modifications generally occur at the transcriptional levels, such as 
DNA methylation, histone modifications and microRNA (miRNA) expression. 
Studies have shown that aberration in epigenetics is known to increase susceptibility 
to NAFLD [23]. DNA methylation has a crucial epigenetic determinant in NAFLD 
progression, which is influenced by dietary methyl donor deficiency. Betaine, 
choline and folate are common methyl donors [24]. Sirtuins (SIRTs) are a group of 
proteins with deacetylase activity mainly involved in epigenetic modification. SIRTs 
have been implicated in regulating proteins involved in metabolic processes like 
lipid metabolism, oxidative stress, glucose metabolism and inflammatory pathways. 
Research findings in animal and human models showed that NAFLD is associ-
ated with lowered SIRT1 levels [25]. Recent studies demonstrated the association 
between miRNA levels and NAFLD pathogenesis. Krützfeldt et al. (2005) showed 
inhibition of miRNA-122 led to decreased plasma cholesterol levels and reduced 





The pathogenesis of NAFLD is also dependent on dietary factors. The quantity 
of calorie intake and the diet’s quality concerning nutrients decide a healthy diet. 
Diet rich in fructose is associated with NAFLD. Fructose is a lipogenic dietary factor 
with pro-inflammatory activity, causing oxidative stress and increased expression 
of TNF-α. Studies demonstrated that fructose intake in patients with NAFLD leads 
to increased fibrosis [27]. Diet rich in mono-unsaturated fatty acids showed protec-
tive effects by improving steatosis and insulin resistance in NAFLD patients [28]. 
Studies conducted in ob/ob mice showed less steatosis and lowered liver enzyme 
levels upon a moderate alcohol administration level [29].
3.4 Gut microbiota
Recent studies showed the involvement of the gut-liver axis in the pathogenesis 
of NAFLD [30]. Bacterial toxins like lipopolysaccharides (LPS) are the potent toxins 
released by gut bacteria. LPS activate inflammatory response by activating stress-
activated protein kinase, JNK, p38 affecting insulin resistance, obesity, hepatic fat 
accumulation and NASH development [31]. Patients with NAFLD have increased 
gut permeability and higher bacterial growth than normal subjects [32].
4. Functional foods for NAFLD
Human history’s survival has always been highly reliant on food to avoid or 
battle the diseases. Hippocrates, the renowned physician, quoted, “Let food be 
thy medicine and medicine be thy food.” Functional foods should not contradict 
the scientific advancements made to treat degenerative diseases over the last two 
centuries. Due to modern nomadic lifestyle and the shift in natural resources, 
traditional agricultural practices and dietary habits are not standard in this decade. 
Anti-NAFLD compounds, in general, must be discerning and innocuous. They 
should look at molecular and metabolic levels to reduce fat deposition in the liver. 
Flavones such as quercetin, hesperetin from onions and citrus fruits were shown 
to reduce fatty acid deposition in the liver. Anti-NAFLD compounds’ mechanism 
must be reversible in the event NAFLD needs, for example, to promote the tissue 
darning subsequent injury. Most food-derived compounds show reversible activ-
ity [33]. The flavonoid, naringenin dose-dependently and reversibly inhibited 
transforming growth factor-β (TGF-β) and vascular endothelial growth factor 
(VEGF), thereby modulated the fatty acid oxidation and trafficking dependent 
liver  inflammation [34].
Pre-clinical and clinical models have proven their worth to test natural com-
pounds for anti-NAFLD activities. Many anti-NAFLD compounds such as flavones, 
anthraquinones, stilbenes, naphthols and polysaccharides showed potency at 
cellular levels, phase I and II clinical trials [35]. Epidemiological studies illustrated 
that populations gobble such bioactive substances have low disability rates as their 
main diets. Since these compounds are food endogenous, the fortifying meal is 
a relatively cheap way of delivering them throughout a lifetime, as many people 
tend to forget pills over long periods. It was suggested that the use of non-alcoholic 
steatohepatitis inhibitors might not prove relevant, as these inhibitors may be more 
efficient against the progression of disease at an early stage as comparing when a 
metastatic illness has progressed to advanced stages [36]. Meanwhile, the onset or 
evolution of the process of non-alcoholic steatohepatitis and cirrhosis generally 
take months or years; continual intake of anti-NAFLD compounds might be the 
ultimate approach to inhibit NAFLD-related molecular and metabolic stimulators 
chronically.
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Most NAFLD inhibitors of diet can inversely inactivate more than one stimulator 
of fatty liver disease, making them favorable over irreversible inhibitors with one 
specificity and substantial lethal side effects. Inhibitors of nutrition sources, such 
as silymarin and morin, are reversible and appear to target multiple activators and 
inhibitors of NAFLD [37]. NAFLD inhibitors seem immune or could delay drug 
resistance in standard therapy to develop drug resistance by prolonging cells [38]. 
These assets converse to these bioactive composites to bypass drug resistance and 
be effective against several types of non-alcoholic fatty liver dependent diseases. 
NAFLD is a widely down-regulated co-fetal mechanism in healthy populations. 
NAFLD targeting does not lead to side effects even after chronic exposure to natu-
rally occurring and physiological anti-NAFLD compounds.
Low molecular weight anti-NAFLD functional foods such as antioxidants, 
pre- or probiotics, tangeritin and lycopene may offer novel strategies in NAFLD 
dependant insulin resistance, obesity and abnormal fatty acid metabolism-related 
hepatocellular carcinoma [39]. Orally administered lycopene was detected in the 
liver and plasma and brain cortex of the rat model of various diseases with numer-
ous concentrations [40]. Reviews on the work of several types of research on a 
diversity of anti-NAFLD functional foods, the non-alcoholic fatty liver-associated 
enzymes they inhibit, the right sources of NAFLD compounds, the molecular 
mechanisms of inhibition and references for additional information. The list is not 
meticulous. Minerals have some negative role on NAFLD and the existed clinical 
data showed that Zinc (Zn), selenium (Se) and Copper (Cu) have some negative 
impact on anti-NAFLD [41].
4.1 Phenolic compounds
4.1.1 Catechins
Oolong tea polyphenols markedly inhibited the formation of oxidized lipids, 
reduced body fat and the risk of developing arteriosclerosis [42]. A double-blind 
placebo-controlled study by Sakata et al. (2013) demonstrated the health benefits of 
green tea extracts for NAFLD [43]. The green tea polyphenols showed higher bio-
availability in the serum following its consumption. Antioxidant, anti-inflammation, 
lipid metabolism-related biomarkers, as well as SREBPs and related genes, are critical 
mediators of NAFLD. Epigallocatechin-3-gallate (EGCG), a critical bioactive from 
green tea, prevented NAFLD in several experimental models (Table 1) [44].
4.1.2 Curcumin
Curcumin, a yellow-pigmented bioactive of Curcuma longa, is most commonly 
used as a dietary spice. Numerous investigations described its pharmacological 
activities, including antioxidant, lipid-modifying, anti-inflammatory, anti-cancer 
effects [45]. Oral administration of curcumin (50 mg/kg body weight) synergisti-
cally regulated both endogenous and exogenous Nrf2/LXRα pathways in high 
sucrose diet-induced NAFLD rats [46]. Jazayeri et al. (2019) showed curcumin 
regulated the PPAR-γ activity, inhibited cyclooxygenase controlled inflammation 
and improved NAFLD [46, 47]; Curcumin (100 mg/kg body weight) administra-
tion for three weeks to methionine and choline-deficient (MCD) diet-fed mice 
significantly upregulated superoxide dismutase 1 (SOD1), SIRT1 levels and inhib-
ited O-GlcNAcylation pathway [48]. Saadati et al. (2019) conducted a randomized 
placebo-controlled clinical trial with 52 NAFLD subjects where they showed 
curcumin (1500 mg) administration for 12 weeks significantly reduced serum 
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Reduced liver steatosis [121]
Antioxidant, anti-inflammatory, 
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Insulin resistance;
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Inhibit CYP3A and CYP2C9;
downregulate HNF4α,
Andrographis paniculata Improved glucose 








Upregulate Glycogen synthesis, PDase 
and GSK3β
Herbliquorice Decreased hepatic 
lipogenesis
[72]
PHYTOSTEROLS Antioxidant, Lipid-modifying Downregulate TGF-β, IL-6, IL-10, 
C-reactive protein, lipoprotein 
cholesterol (LDL-C) and hepatic TG
Unrefined plant oils, Nuts Increased liver lipid 
metabolism
[77]
CAROTENOIDS Antioxidant, anti-inflammatory Downregulate Malondialdehyde, 
TNF-α
Carrots, guava, mangoes, 
collard greens








Isoflavones exhibited an excellent therapeutic effect for NAFLD through de novo 
lipogenesis via ChREBP and anti-adipogenic Wnt signaling [50]. Genistein derived 
from soybean is the most investigated isoflavone with higher potency against 
NAFLD. Genistein supplementation (2 and 4 g/kg diet) for 12 weeks markedly 
reduced serum and liver lipids and downregulated SREBP-1c, PPAR-γ in NAFLD 
mice [51]. Genistein significantly suppressed the expression of cyclooxygenase-1 
and hepatic thromboxane A2 receptor expression through the thromboxane A2 
(TXA2) pathway [52]. Daidzein, a naturally occurring phytoestrogen occurring 
in soybean and legumes, reduced NAFLD risk and inhibited hepatic fatty acid 
β-oxidation in high fat supplemented mice [53]. Liu et al. (2017) showed adminis-
tration of soy isoflavone (10 or 20 mg/kg) to NAFLD animals inhibited fatty acid 
synthesis. It promoted fat oxidation in the liver by regulating the expression of 
SREBP-1c and PPARα [54].
4.1.4 Resveratrol
Resveratrol (3, 5, 4′-trihydroxystilbene) is widely present in the skin of grapes, 
berries and peanuts. Oral administration of resveratrol (50 mg/kg body weight) to 
high-fat diet (HFD)-induced C57BL/6 J mice reduced inflammation and fibrosis 
risk by modulating the IκBα-NF-κB and autophagic pathway [55]. Resveratrol by 
upregulating SIRT1 decreased liver lipogenesis markers and improved lipid metabo-
lism in HFD fed mice [56]. Intragastric administration of resveratrol improved 
hepatic steatosis mediated by a SIRT1/ATF6-dependent mechanism in HFD fed 
mice [57]. Theodotou et al. (2019) showed supplementation of trans-resveratrol 
as a micronized formulation to NAFLD subjects reduced TG accumulation and 
improved insulin resistance via activation of 5′ adenosine monophosphate-activated 
protein kinase (AMPK) and SIRT1 [58].
4.2 Proanthocyanidins and flavonoids
The oligomeric and polymeric components of the flavonoid biosynthetic path-
way are proanthocyanidins, also known as condensed tannins. Proanthocyanidins 
are widely distributed in seeds, fruits, flowers, nuts, barks of several plants and are 
typically made up of catechin and epicatechin [59]. The number of anti-NAFLD 
proanthocyanidins published studies is less, but findings are similar to those of 
other flavonoids (Figure 2). The grape seed proanthocyanidins (GSP) exhibited 
anti-NAFLD effect mainly by lipid-lowering and high antioxidant activities [60]. 
In another study, GSP suppressed high calorie diet-induced hepatic injury in 
animals [61]. A significant number of studies demonstrated the hepatoprotective 
and anti-fibrotic effect of morin in NAFLD models, mainly by modulating the key 
signaling pathways associated with fibrosis [62]. Administration of polymethoxyl-
ated flavones enriched Daoxianyeju extracts (0.2% and 0.5%) to HFD fed mice 
prevented liver inflammation and steatosis by activating nuclear factor erythroid-2 
related factor 2 (Nrf2) signaling [63]. Tannic acid supplementation to the west-
ern diet-fed mice for 12 weeks suppressed histone acetyltransferase activity and 
prevented lipid accumulation [64]. Silybin, also known as silibinin, derived from 
Silybum (milk thistle) plant extracts in combination with tangeretin (75–150 mg/
kg) showed potent antioxidant, anti-inflammatory and anti-fibrotic activities [65]. 
Citrus peel extract composed of hesperidin, narirutin, synephrine and tangeretin 
prevented in vivo lipid accumulation and fatty liver development by regulating 
AMPK  activation [66].
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4.3 Saponins and terpenes
Saponins consist of a broad family of structurally similar substances with steroid 
or triterpenoid glycone (Sapogenin) containing more than a fraction of oligosac-
charides. The saponins and their derivatives are reported in several edible legumes. 
Several in vivo studies documented legume saponins’ health benefits, including 
antioxidant, antidiabetic, hepatoprotective, hypocholesterolemic, anti-cancer, 
antitumor, antiviral [67]. Treatment of Akebia saponin D (100 μM) to oleic acid-
induced BRL cells reduced lipid accumulation, increased BNip3 levels and mitoph-
agy [68]. Hou et al. (2020) demonstrated oral administration of ginsenoside-Rg1 
(30 mg/kg/day) reduced SREBP-1c expression, lipid accumulation and alleviated 
liver inflammation in NAFLD rats [69]. Sea cucumber-derived saponins echinoside 
A (EA) ameliorated orotic acid induced-NAFLD mainly by inhibiting lipogenesis 
genes. Andrographolide, a diterpene lactone present in Andrographis paniculata 
treatment to choline-deficient amino acid-defined mice, prevented liver inflamma-
tion, reduced macrophage infiltration and inflammation activation [70, 71].
Wang et al. (2016) observed glycyrrhizic acid (a natural triterpene glycoside) 
administration to MCD diet-fed mice significantly inhibited hepatic stellate cell 
activation and collagen deposition [72]. In a similar study, glycyrrhizic acid sup-
pressed lipid accumulation and reduced the levels of SREBP-1c, FAS, SCD-1 in HFD 
fed mice [73]. Glycyrrhetinic acid, a bioactive triterpenoid from licorice, reduced 
the inflammation and fat content in the mouse liver and inhibited AKR1B10 
 activity [74].
4.4 Phytosterols
Phytosterols or plant sterols are cholesterol-like molecules which perform vital 
structural functions in plants. Phytosterols are best known for their cholesterol-
lowering effects and recent investigations highlighted their anti-fibrotic develop-
ments in key NAFLD models [75]. Plant sterol and stanol ester supplementation 
significantly reduced plasma lipids and prevented HFD induced inflammation in 
experimental animals [76]. In a high-fat Western-style diet-induced mice study, 
stigmasterol and β-sitosterol markedly reduced the liver TGs, cholesterol, intes-
tinal bile acid levels and alleviated NAFLD [77]. Intragastric administration of 
phytosterol esters for 12 weeks to HFD fed rats reduced liver size, lipid content and 
improved intestinal flora [78]. In combination with EPA and DHA, phytosterol 
Figure 2. 
Significance of functional foods for NAFLD.
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esters significantly reduced the levels of TGs, cholesterol, LDL cholesterol and 
decreased the pro-inflammatory cytokines in NAFLD subjects [79]. β-sitosterol 
supplementation for 12 weeks mitigated high-fructose diet-induced macrovesicular 
steatosis and progression of steatohepatitis [80].
4.5 Carotenoids
Carotenoids are a family of poly-isoprenoid structured and fat-soluble pigments 
that occur naturally in plants and microbes. The primary sources of carotenoids in 
the human diet are yellow, orange and red-colored fruits and vegetables. In the last 
few decades, carotenoids have been the main focus of research mainly due to their 
potent antioxidant, anti-inflammatory and anticancer properties [81]. Besides, 
carotenoids were also reported for their anti-fibrotic effect in several experimental 
NAFLD models [82]. Several clinical studies revealed circulatory carotenoid levels 
to NAFLD risk [83, 84]. β-carotene is reported for strong antioxidant potential 
and a vast number of in vitro and in vivo studies revealed the hepatoprotective 
and anti-fibrotic effect of β-carotene [85–87]. Lycopene, a non-provitamin A 
carotenoid, mainly exhibited hepatoprotective effect through scavenging ROS. 
Supplementation of lycopene significantly lowered steatosis and obesity-induced 
inflammation in NAFLD animals [88–91]. The xanthophyll carotenoid, astax-
anthin is reported for various biological effects such as free radical scavenging, 
ocular protective, hepatoprotective, anti-aging, anti-diabetic, anti-inflammatory, 
anticancer, etc. [92–94]. In experimental liver fibrosis models, astaxanthin offered 
hepatoprotection by reducing liver pro-inflammatory cytokines, attenuating insulin 
resistance, downregulating key signaling pathways [95–99]. Other carotenoids like 
α-carotene, lutein and zeaxanthin also exerted hepatoprotection in experimental 
NAFLD models [100–102].
4.6 Functional foods from plant/animal origin/carbohydrates
Oats (Avena sativa) rich in β-glucan, a polysaccharide responsible for its func-
tional properties and other active compounds such as antioxidants, vitamins, 
minerals and phenolic compounds and dietary fibers. A study conducted in 
Sprague–Dawley rats found that a diet rich in oats increased liver LDLR, reduced 
liver TGs and cholesterol, thereby preventing NAFLD development to liver cirrhosis 
[103]. Flaxseed (Linum usitatissimum) is a highly nutritional functional food due 
to active components such as polyunsaturated fatty acid (PUFA), α-linolenic acid, 
proteins, lignans, soluble and insoluble dietary fibers, antioxidants and phytoestro-
gens. In a clinical trial conducted with 50 subjects, supplementation of flaxseed diet 
significantly reduced the body weight, liver enzymes, insulin resistance, hepatic 
fibrosis and steatosis. A significant difference was observed between control and 
flaxseed groups in ALT, AST, GGT, fibrosis score and steatosis score, etc. [104].
Choline is an essential nutrient present in eggs, liver, soy wheat and vegetables. 
Choline is either produced in the body or is absorbed from a diet rich in phospholip-
ids such as phosphatidylcholine. Phosphatidylcholine is a significant component of 
cell membranes and present in egg yolk and soy. Choline and betaine supplementa-
tion effectively alleviated NAFL in dairy cattle, PEMT- deficient mice by increas-
ing AMPK, reducing mRNA levels of DGAT2 and lipid accumulation, decreased 
expression of genes such as acyl-CoA synthase-1 and -4, mitochondrial glycerol 
phosphate acyltransferase, etc. [105]. Studies conducted in humans showed that 
betaine supplementation reduced serum concentrations of ALT and AST and low-
ered hepatic steatosis [106, 107]. In Balb/c mice, administration of betaine increased 
serum ALT, decreased hepatic and visceral mass accumulation by reducing glucose 
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production through inhibiting gluconeogenesis and promoting the use of glucose 
in glycogen production leading to improved serum glucose levels. Thereby, betaine 
reversed insulin resistance by promoting IRS1 phosphorylation and enhanced 
downstream pathways of gluconeogenesis and glycogen synthesis and effectively 
alleviated NAFLD [108].
4.7 Functional foods from microbial origin
Monascus is a fungi class that includes M. purpureus, M. pilosus and M. ruber 
relevant in the field of functional food due to the presence of bioactive metabolites 
such as monascin and ankaflavin. These compounds possess pharmacological prop-
erties such as antioxidant, anti-inflammatory, antidiabetic, immunomodulatory 
and anticancer [109]. A study conducted in FL83B hepatocytes and male C57BL/6 J 
mice observed that both monascin and ankaflavin inhibited fat accumulation in 
hepatocytes by preventing fatty acid uptake, lipogenesis and accelerating fatty acid 
β-oxidation. Monascin and ankaflavin also improved AMPK phosphorylation and 
downregulated expression of steatosis related genes. Treatment with monascin 
and ankaflavin suppressed expression of SREBP-1c, FAS, ACC and upregulated 
FXR, PGC-1α and PPAR-α. This result suggested that monascin and ankaflavin are 
potential bioactives for NAFLD [110, 111].
Sargassum serratifolium is a brown macroalga that possess several bioactive 
compounds such as sargahydroquinoic acid, sargachromenol, sargaquinoic acid, 
etc. This seaweed is widely used in culinary preparations of Korea and China. S. 
serratifolium have many pharmacological properties such as anti-inflammatory, 
anti-obesity, lipid-lowering, etc. A review of C57BL/6 J mice treated with a rich 
ethanol fraction of S. serratifolium demonstrated lipid-lowering effects by activating 
AMPK-mediated fatty acid oxidation signaling and prevented SREBP-1c signal-
ing related lipogenesis in the liver and fatty tissues. The extract was also able to 
downregulate FAS and SCD-1 along with SREBP-1c and inhibited TG synthesis and 
cholesterol and activated fatty acid oxidation by promoting AMPK. This showed 
that S. serratifolium is a practical, functional ingredient for alleviating NAFLD by 
controlling lipid accumulation in liver [112].
Freshwater clams (Corbicula fluminea) is well-known hepatoprotective used 
in Chinese traditional medicine. The major active components are brassicasterol, 
camesterol, stigmasterol, α-linolenic acid, eicosapentaenoic acid, docosapentaenoic 
acid, docosahexaenoic acid and carotenoids. In HepG2 cells, ethanolic extract of 
residual clam meat significantly decreased lipid accumulation by suppressing FAS. 
In tilapia and mice models, the clam extract reduced AST levels, ALT, total choles-
terol, accumulation of triglycerols, etc. The extract was also able to downregulate 
SCD-1 index, promoted PUFA n3/n6 ratio and reduced ballooning, PGE2, total 
fatty acids, triacylglycerol level, hepatocyte size and inflammation, etc. This result 
showed that freshwater clam extract is a useful functional component for develop-
ing hepatoprotective supplements against NAFL [113].
5. Role of functional foods for NAFLD
There may be limitations to their use in disease prevention in Anti-NAFLD 
functional foods, while there are opportunities to assess functional foods’ ability as 
anti-NAFLD compounds.
1. It will be essential to address the suitable intake of anti-NAFLD compounds 
that confer prevention without toxicity.
Functional Foods
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2. Knowledge about the kinetics of functional foods or their blood metabolite 
levels, which may differ from individuals and diseases, would be required over 
the individual’s lifespan for a sustained level of NAFLD inhibitor in the blood.
3. If clinical evidence shows that a dietary component is successful in disease pre-
vention and broad intervention trials prove effective in reducing those disease-
related biomarkers, then the medical community can embrace the element.
4. How early in life is anti-NAFLD food being consumed?
5. When does one stop using anti-NAFLD functionally in the event of liver 
regeneration, such as fat dissipation?
6. How does one assess whether the prevention of disease progression with anti-
NAFLD functional foods has been affected?
7. Nevertheless, the use of anti-NAFLD compounds, some from natural sources 
and others from synthesis, such as LPSF/GQ-02, have shown successful clini-
cal efficacy. However, Thiazolidinediones (TZD) were addressed by suggest-
ing that acting as an insulin sensitizer effective against insulin resistance and 
fat accumulation could be good anti-NAFLD agents at an early stage NAFLD. 
Anti-NAFLD functional foods can, therefore, be beneficial at the early stages 
of the non-alcoholic fatty liver cycle [114].
8. Data on the toxicity of the anti-NAFLD compound will be needed for diseases 
such as diabetes, where both excessive and insufficient NAFLDs exist, com-
pounds that may inhibit excessive NAFLDs and worsen insufficient NAFLDs 
may need to be established.
9. Most human NAFLD or liver steatosis cells are deficient in PNPLA3 (Patatin 
like phospholipase domain-containing gene. This deficiency in PNPLA3 indi-
cates that high-fat deposition activity after eating and decreases during periods 
of fasting food. It plays a role in toxic clearance hence their responsiveness to 
Anti- NAFLD compounds [115].
6. Bioavailability and synergy of anti-NAFLD functional foods
Low molecular weight anti-NAFLD compounds such as phenolics, terpenes, 
phytosterols, small carbohydrates and amino acids might be more bioavailable than 
high and moderately soluble proteins, polypeptides and large carbohydrate mol-
ecules. Nonetheless, large molecules such as proteins and carbohydrates have shown 
a protective effect against NAFLD. In contrast, substances with low molecular 
weight might help liver regeneration. Combining one or more anti-NAFLD com-
pounds has been shown to result in improved behavior in several studies. Silybin 
treatment, in combination with vitamin E and phosphatidylcholine, significantly 
improved liver enzymes and liver steatosis in NAFLD patients [116]. Another study 
by Han et al. (2014) showed metformin (500 mg orally three times daily) in com-
bination with vitamin E (100 mg) and bicyclol (25 mg) synergistically prevented 
NAFLD in human subjects by improving liver enzymes and liver histology param-
eters. The combination of blueberry juice and probiotics 1.5 mL per 100 g (0.07 mg/
mL concentration) weight showed protection to hepatocyte mitochondrial function 
in the HFD induced animals [117].
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7. Conclusion and future prospects
Even though there is no FDA approved anti-NAFLD compound, industrial and 
academic researchers are still investigating for naturally occurring bioactive(s) 
for potential and safe anti-NAFLD compounds. Prior consideration is necessary 
for designing anti-NAFLD functional foods, especially for complex diseases such 
as insulin resistance, chronic liver diseases, etc. Food bioactive such as curcumin, 
proanthocyanidins that have shown hepatoprotective and anti-NAFLD properties, 
are the right candidates for incorporating into functional foods. Also, research 
support is highly essential for accessing the anti-NAFLD properties of other food 
components. Anti-NAFLD functional foods could be a low-cost strategy to prevent 
obesity-related complications. NAFLD inhibitors are recognized as one of the 
targets for obesity therapy [118]. The development of post-genomic functional 
foods may need to focus on molecular targets such as NAFLD factors that drive the 
early stages of chronic disease onset/progression. A comprehensive and successful 
work in functional foods will involve knowledge of ethnobotany, chemotaxonomy, 
transgenic plants or animal animals (as bioactive compound factories) and interdis-
ciplinary approaches involving foods, nutrition scientists, and biomedical scientists 
for design. In this context, researchers must have in-depth knowledge in the field 
of ethnobotany and chemotaxonomy. To determine the efficacy of functional food, 
the post-genomic wave of functional foods would need to span the entire spectrum, 
from primary to clinical trials.
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Nrf2 Nuclear factor erythroid 2-related factor 2
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ROS Reactive oxygen species
SCD1 Stearoyl-Coenzyme A desaturase-1
SIRT Sirtuins
SNPs  Single Nucleotide Polymorphisms
SOD1 Superoxide dismutase 1
SREBP-1c Sterol regulatory element-binding protein-1c
TG Triglyceride
TGF-β  Transforming growth factor-β
TM6SF2 Transmembrane 6 superfamily member 2
TNF-α  Tumor Necrosis Factor- α
TXA2 Thromboxane A2
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VEGF  Vascular endothelial growth factor
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